Repeated injection of MK801: An animal model of schizophrenia?

Neurochemistry International

Volumn 48, Issue 6-7, 2006, Pages 541-546

  Eyjolfsson, Elvar M ^a   Brenner, Eiliv ^a   Kondziella, Daniel ^a,b   Sonnewald, Ursula ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

1,2 13C acetate; 1 13C glucose; GABA; Glutamate; Metabolism; MK801; NMDA; NMR spectroscopy

Indexed keywords

ACETIC ACID; CARBON 13; DIZOCILPINE; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROTON;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; BRAIN METABOLISM; BRAIN REGION; CARBON NUCLEAR MAGNETIC RESONANCE; CELL METABOLISM; CINGULATE GYRUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MEGADOSE; FRONTAL CORTEX; INJECTION; ISOTOPE LABELING; LOCOMOTION; MALE; NERVE CELL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SCHIZOPHRENIA; TEMPORAL LOBE;

ACETIC ACID; ANIMALS; ASTROCYTES; BRAIN; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; INJECTIONS, INTRAPERITONEAL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MOTOR ACTIVITY; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; TISSUE EXTRACTS;

ANIMALIA;

EID: 33645851976     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2005.11.019     Document Type: Article

References (36)

1. Bartha R., Williamson P.C., Drost D.J., Malla A., Carr T.J., Cortese L., Canaran G., Rylett R.J., and Neufeld R.W. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 54 (1997) 959-965
2. Bensimon G., Lacomblez L., and Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 330 (1994) 585-591
3. Brenner E., Kondziella D., Haberg A., and Sonnewald U. Impaired glutamine metabolism in NMDA receptor hypofunction induced by MK801. J. Neurochem. 94 (2005) 1594-1603
4. Bullock M.R., Merchant R.E., Carmack C.A., Doppenberg E., Shah A.K., Wilner K.D., Ko G., and Williams S.A. An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage. Ann. N.Y. Acad. Sci. 890 (1999) 51-58
5. Carlsson A.W.N., and Carlsson M. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol. Psychiatry 46 (1999) 1388-1395
6. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 65 (2001) 1-105
7. Davis S.M., Lees K.R., Albers G.W., Diener H.C., Markabi S., Karlsson G., and Norris J. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 31 (2000) 347-354
8. Farber N.B., Foster J., Duhan N.L., and Olney J.W. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr. Res. 21 (1996) 33-37
9. Farber N.B., Hanslick J., Kirby C., McWilliams L., and Olney J.W. Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology 18 (1998) 57-62
10. Farber N.B., Kim S.H., Dikranian K., Jiang X.P., and Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol. Psychiatry 7 (2002) 32-43
11. Farber N.B., Wozniak D.F., Price M.T., Labruyere J., Huss J., St P.H., and Olney J.W. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?. Biol. Psychiatry 38 (1995) 788-796
12. Flores C., and Coyle J.T. Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine. Neuropsychopharmacology 28 (2003) 1227-1234
13. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158 (2001) 1367-1377
14. Harrison L., Penny W.D., and Friston K. Multivariate autoregressive modeling of fMRI time series. Neuroimage 19 (2003) 1477-1491
15. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10 (2005) 40-68
16. Heckers S., and Konradi C. Hippocampal neurons in schizophrenia. J. Neural. Transm. 109 (2002) 891-905
17. Himmelseher S., and Durieux M.E. Revising a dogma: ketamine for patients with neurological injury?. Anesth. Analg. 101 (2005) 524-534
18. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
19. Kim S.H., Price M.T., Olney J.W., and Farber N.B. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-adrenergic agonists. Mol. Psychiatry 4 (1999) 344-352
20. Kondziella, D., Brenner, E., Eyjolfsson, E.M., Markinhuhta, K.R., Carlsson, M., Sonnewald, U., 2005. Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure. Neuropsychopharmacology. [Epub ahead of print].
21. Lewis D.A., Hashimoto T., and Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6 (2005) 312-324
22. Muir K.W., and Lees K.R. Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst. Rev. 3 (2003) CD001244
23. Olney J.W., and Farber N.B. NMDA antagonists as neurotherapeutic drug, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 3 (1995) 335-345
24. Olney J.W., and Farber N.B. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J. Clin. Psychiatry 55 Suppl. B (1994) 43-46
25. Olney J.W., Labruyere J., and Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244 (1989) 1360-1362
26. Schulz B., Fendt M., Pedersen V., and Koch M. Sensitization of prepulse inhibition deficits by repeated administration of dizocilpine. Psychopharmacology (Berl) 156 (2001) 177-181
27. Smith P.F. Therapeutic N-methyl-d-aspartate receptor antagonists: Will reality meet expectation?. Curr. Opin. Investig. Drugs 4 (2003) 826-832
28. Sonnewald U., Westergaard N., and Schousboe A. Glutamate transport and metabolism in astrocytes. Glia 21 (1997) 56-63
29. Tamminga C.A. Schizophrenia and glutamatergic transmission. Crit. Rev. Neurobiol. 12 (1998) 21-36
30. Tebartz van E.L., Valerius G., Buchert M., Thiel T., Rusch N., Bubl E., Hennig J., Ebert D., and Olbrich H.M. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol. Psychiatry. 58 (2005) 724-730
31. Theberge J., Al-Semaan Y., Williamson P.C., Menon R.S., Neufeld R.W., Rajakumar N., Schaefer B., Densmore M., and Drost D.J. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am. J. Psychiatry 160 (2003) 2231-2233
32. Theberge J., Bartha R., Drost D.J., Menon R.S., Malla A., Takhar J., Neufeld R.W., Rogers J., Pavlosky W., Schaefer B., Densmore M., Al-Semaan Y., and Williamson P.C. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry 159 (2002) 1944-1946
33. Tsai G., and Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 165-179
34. Waniewski R.A., and Martin D.L. Preferential utilization of acetate by astrocytes is attributable to transport. J. Neurosci. 18 (1998) 5225-5233
35. Wozniak D.F., Brosnan-Watters G., Nardi A., McEwen M., Corso T.D., Olney J.W., and Fix A.S. MK-801 neurotoxicity in male mice: histologic effects and chronic impairment in spatial learning. Brain Res. 707 (1996) 165-179
36. Wozniak D.F., Dikranian K., Ishimaru M.J., Nardi A., Corso T.D., Tenkova T., Olney J.W., and Fix A.S. Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: potential relevance to Alzheimer's disease. Neurobiol. Dis. 5 (1998) 305-322